

Sustainability Accounting Standard Board (SASB) index 2025

The Novartis SASB index aligns with the Biotechnology & Pharmaceuticals Sustainability Accounting Standard (industry standard | version 2023-12). Information referenced has been sourced from our Report on Nonfinancial Matters, Annual Report/Form 20-F, ESG Data Summary, corporate website, Novartis public policies and positions, and public databases or selected materials from third parties where applicable. For additional information about our ESG practices, please visit <https://www.novartis.com/esg>.

Disclosure	Reference
Safety of Clinical Trial Participants	
HC-BP-210a.1 Discussion, by region, of management process for ensuring quality and patient safety during clinical trials	Report on Nonfinancial Matters 2025, page 34 Novartis commitment to patients and caregivers Human Rights Commitment Statement Ethics in Clinical Trials
HC-BP-210a.1 Number of inspections related to clinical trial management and pharmacovigilance that resulted in: (1) entity voluntary remediation or (2) regulatory or administrative actions taken against the entity	ESG Index: quality and supply ESG Data Summary 2025, page 2
HC-BP-210a.1 Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	All significant legal proceedings are disclosed within the Annual Report and accounts (Annual Report 2025, Item 18. Note 20)
Access to Medicines	
HC-BP-240a.1 Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	Report on Nonfinancial Matters 2025, page 35 Access to Medicine Index 2024
HC-BP-240a.2 List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	Novartis has malaria products on the WHO List of Prequalified Medicinal Products
Affordability & Pricing	
HC-BP-240b.2 Percentage change in: (1) weighted average list price and (2) weighted average net price across product portfolio compared to previous reporting period	Not reported
HC-BP-240b.3 Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous reporting period	Not reported
Drug Safety	
HC-BP-250a.1 Products listed in public medical product safety or adverse event alert databases	Available via FDA Adverse Event Reporting System (openFDA)
HC-BP-250a.2 Number of fatalities associated with products	Available via FDA Adverse Event Reporting System (openFDA)
HC-BP-250a.3 (1) Number of recalls issued, (2) total units recalled	Report on Nonfinancial Matters 2025, page 35
HC-BP-250a.4 Total amount of product accepted for takeback, reuse, or disposal	Report on Nonfinancial Matters 2025, page 35
HC-BP-250a.5 Number of enforcement actions taken in response to violations of good manufacturing practices (GMP) or equivalent standards, by type	ESG Index: quality and supply ESG Data Summary 2025, page 2

Disclosure	Reference
Counterfeit Drugs	
HC-BP-260a.1 Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	ESG Index: quality and supply Novartis Position on Falsified Medical Products
HC-BP-260a.2 Discussion of process for alerting customers and business partners to potential or known risks associated with counterfeit products	ESG Index: quality and supply
HC-BP-260a.3 Number of actions that led to raids, seizure, arrests, or filing of criminal charges related to counterfeit products	ESG Index: quality and supply
Ethical Marketing	
HC-BP-270a.1 Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	All significant legal proceedings are disclosed within the Annual Report and accounts (Annual Report 2025, Item 18. Note 20)
HC-BP-270a.2 Description of code of ethics governing promotion of off-label use of products	Report on Nonfinancial Matters 2025, page 37 The Novartis Code of Ethics Doing Business Ethically Policy
Employee Recruitment, Development & Retention	
HC-BP-330a.1 Discussion of talent recruitment and retention efforts for scientists and research and development staff	Careers in research and development US Biomedical Research internship programs
HC-BP-330a.2 (1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others	Report on Nonfinancial Matters 2025, page 12
Supply Chain Management	
HC-BP-430a.1 Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	Novartis quality management system (QMS) External Partner Risk Management (EPRM) ESG Data Summary 2025, page 2
Business Ethics	
HC-BP-510a.1 Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	All significant legal proceedings are disclosed within the Annual Report and accounts (Annual Report 2025, Item 18. Note 20)
HC-BP-510a.2 Description of code of ethics governing interactions with health care professionals	Report on Nonfinancial Matters 2025, page 38 The Novartis Code of Ethics Doing Business Ethically Policy
Activity Metrics	
HC-BP-000.A Number of patients treated	Report on Nonfinancial Matters 2025, page 36
HC-BP-000.B Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	Products ESG Data Summary 2025, page 2